前收市價 | 43.20 |
開市 | 44.88 |
買盤 | 42.71 x 200 |
賣出價 | 42.85 x 200 |
今日波幅 | 42.67 - 45.51 |
52 週波幅 | 31.52 - 54.98 |
成交量 | |
平均成交量 | 717,323 |
市值 | 3.554B |
Beta 值 (5 年,每月) | 0.66 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -8.25 |
業績公佈日 | 2024年8月01日 - 2024年8月05日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 89.30 |
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript May 2, 2024 Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.02505 EPS, expectations were $-1.72. RARE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome […]
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.